A groundbreaking HIV prevention treatment is making waves in Africa, offering hope and a potential turning point in the fight against the virus. Lenacapavir, a twice-yearly injection, has shown remarkable results, reducing HIV transmission risk by an astonishing 99.9%. This innovative approach is akin to a powerful vaccine, and its real-world application is now being witnessed in countries like South Africa, Zambia, and Eswatini.
In South Africa, where HIV prevalence is high, with one in five adults affected, a research unit at Wits University has overseen the initial rollout. This initiative, funded by Unitaid, an international health agency, aims to ensure equitable access to such medical innovations. Unitaid announced that the first individuals in South Africa have started using lenacapavir for HIV prevention, marking a significant step towards addressing the HIV epidemic in low- and middle-income countries.
However, there are concerns about the cost and availability of this treatment. In the United States, the drug costs a staggering $28,000 per person annually, and Unitaid has not disclosed the number of people who received the initial doses. A broader national rollout is expected next year, but the question of affordability remains a critical issue.
Zambia and Eswatini, South Africa's neighbors, received 1,000 doses last month as part of a US program. The launch of lenacapavir was celebrated at World AIDS Day ceremonies, with vibrant public events in both countries. In Eswatini's Hhukwini constituency, people lined up for the injection, accompanied by song and dance, highlighting the community's enthusiasm and hope.
Prime Minister Russell Dlamini of Eswatini emphasized the significance of this moment, stating, "Today marks a turning point in our national HIV response." He added that the injection offers "fresh hope and a powerful tool to protect our citizens." Similarly, in Zambia, hundreds marched to mark the occasion, and Health Minister Elijah Muchima urged volunteers living with HIV to get the jab, emphasizing its potential to bring "renewed hope" to vulnerable populations.
Under the US program, Gilead Sciences, the manufacturer, has agreed to provide lenacapavir at no profit to two million people in high HIV burden countries over three years. However, there is a notable absence of South Africa from this program, despite its participation in clinical trials. This decision has sparked controversy, with senior US State Department official Jeremy Lewin stating, "We encourage every country, especially countries like South Africa, to fund doses for their own population."
Critics argue that the US deliveries fall short of actual needs and that the market price is prohibitively high for most people. According to 2024 UNAIDS data, Eastern and Southern Africa account for approximately 52% of the 40.8 million people living with HIV worldwide. In Zambia alone, around 1.4 million people are living with HIV, with 30,000 new infections annually, as reported by the health ministry. Eswatini, a small kingdom, has approximately 220,000 people living with the virus.
UNAIDS Executive Director Winnie Byanyima has criticized the limited availability of lenacapavir, stating that drugmakers are neglecting Africa's needs. She urged, "If you don't care about those lives, at least care about the profit! Bring the drug here." WHO Chief Tedros Adhanom Ghebreyesus also warned that progress against HIV is at risk due to funding cuts and called for countries to rapidly increase the use of lenacapavir.
Generic versions of lenacapavir are expected to be available from 2027 at a more affordable price of around $40 per year in over 100 countries. This development is a result of agreements between Unitaid and the Gates Foundation with Indian pharmaceutical companies.
Pre-exposure prophylaxis (PrEP) has been used for over a decade to prevent HIV, but its reliance on a daily pill has limited its global impact. Lenacapavir's long-acting formulation offers a promising alternative, providing a more convenient and effective prevention method.
And this is the part most people miss: the potential impact of lenacapavir on HIV prevention is immense, but its accessibility and affordability remain critical challenges. As we witness the early stages of this treatment's rollout, it's essential to consider the broader implications and ensure that this powerful tool reaches those who need it most.
What are your thoughts on the potential of lenacapavir and the challenges it faces in reaching those at risk? Share your insights and let's spark a conversation about this crucial development in HIV prevention.
